

Market Announcement

4 December 2018

CardieX Limited (ASX: CDX) - Trading Halt

Description

The securities of CardieX Limited ('CDX') will be placed in trading halt at the request of CDX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 6 December 2018 or when the announcement is released to the market.

Issued by

Belinda Chiu

Senior Adviser, Listings Compliance (Sydney)



4 December 2018

Elvis Onyura

By Email

To: Lisa.Banh@asx.com.au; tradinghaltssydney@asx.com.au

Dear Sir.

RE: Request for Trading Halt on Securities of CardieX Limited

(ASX: CDX)

Pursuant to Listing Rule 17.1 and pending a material announcement regarding the Company's capital raising activity, CDX formally applies for a trading halt to be put in place pre-commencement of trade today and to be in place until commencement of trade 6 December 2018 or when that announcement is released to the market.

CDX is not aware of any reason why the Company's request for a trading halt should not be granted.

Yours sincerely,

CARDIEX LIMITED

JARROD WHITE

CHIEF FINANCIAL OFFICER | COMPANY SECRETARY

For more information please contact:

Chief Financial Officer | Company Secretary Jarrod White jwhite@cardiex.com

Investor Relations
Peter Taylor
Physical 412 036 33

Ph: +61 412 036 231

peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology.